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Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is a single-gene disorder of the cerebral small blood vessels caused by mutations in 
the Notch3 gene. The exact prevalence of this disorder was unknown currently, and the number 
of reported CADASIL families is steadily increasing as the clinical picture and diagnostic ex-
aminations are becoming more widely known. The main clinical manifestations are recurrent st-
roke, migraine, psychiatric symptoms, and progressive cognitive impairment. The clinical course 
of CADASIL is highly variable, even within families. The involvement of the anterior temporal 
lobe and the external capsule on brain magnetic resonance imaging was found to have high sen-
sitivity and specificity in differentiating CADASIL from the much more common sporadic cere-
bral small-vessel disease (SVD). The pathologic hallmark of the disease is the presence of gran-
ular osmiophilic material in the walls of affected vessels. CADASIL is a prototype single-gene 
disorder that has evolved as a unique model for studying the mechanisms underlying cerebral 
SVD. At present, the incidence and prevalence of CADASIL seem to be underestimated due to 
limitations in clinical, neuroradiological, and genetic diagnoses of this disorder.
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Introduction
Cerebral small-vessel diseases (SVDs) are a major disease 
burden in most developed countries.
1 SVDs usually manifest 
with lacunar infarction, intracerebral hemorrhage (ICH), and 
subcortical vascular dementia. Although hypertension and 
diabetes mellitus are known to be important risk factors for 
SVDs, many hereditary or idiopathic SVDs have also been 
identified. Among them, cerebral autosomal dominant arteri-
opathy with subcortical infarcts and leukoencephalopathy 
(CADASIL) is the most common single-gene disorder of the 
cerebral small blood vessels and is caused by mutations in 
the Notch3 gene.
2 The main clinical manifestations are recur-
rent stroke, cognitive deficits, migraines, and psychiatric dis-
turbances. Although the exact prevalence of this disorder is 
not known, CADASIL has been reported worldwide in many 
ethnic groups. The increasing availability of diagnostic ex-
pertise and genetic testing has lead to a gradual increase in 
the number of reports about patients with CADASIL. This 
review summarizes the historical background, epidemiology, 
genetics, pathophysiology, characteristic clinical findings, 
neuroimaging, and treatment of this unique disorder.
History
CADASIL was possibly first reported in 1955, when Van 
Bogaert described two sisters with rapidly progressive sub-
cortical encephalopathy of Binswanger’s type.
3 In 1977, Sou-
rander and Walinder reported a Swedish family with multi-
infarct dementia of autosomal dominant inheritance.
4 They 
presented with pyramidal, bulbar, and cerebellar symptoms, 
a relapsing course, and gradually evolving severe dementia. 
The illnesses began in early adulthood (ranging from 29 to 
38 years of age) and generally lasted for 10 to 15 years. Post-
mortem studies showed multiple small cystic infarctions, lo-
calized in the central gray matter, white matter, and pons, CADASIL
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caused by an occlusion of small intracerebral and leptomen-
ingeal arteries. In the same year, Stevens et al.
5 described fa-
milial vascular dementia in an English family with autoso-
mal dominant inheritance. However, their mean age at the on-
set was 50 years (ranging from 39 to 57 years), and their 
mean age at death was 60 years (ranging from 56 to 65 
years). The affected patients presented with a wide variety of 
transient motor, sensory, and other symptoms of vascular ori-
gin. The episodes varied considerably in frequency and se-
verity within a family. The progressive phase of this illness 
was characterized by dementia, bulbar palsy with immobili-
ty, and urinary incontinence. Multiple small infarctions were 
seen in the basal ganglia, thalamus, and cerebral white mat-
ter at autopsy. Small arteries and arterioles showed medial 
swelling with vacuolar degeneration of smooth-muscle cells. 
A recent study demonstrated that hereditary multi-infarct de-
mentia in the Swedish family reported by Sourander and 
Walinder was unrelated to CADASIL. This disorder does not 
affect the Notch3 gene, and these patients do not show char-
acteristic features of CADASIL on pathologic examination.
6 
From the late 1980s to early 1990s there were several Euro-
pean reports of autosomal dominant cerebral SVDs charac-
terized by recurrent stroke, progressive dementia, and mi-
graine. In 1993, Tournier-Lasserve et al.
7 applied linkage 
analysis to two large, unrelated French families presenting 
with CADASIL (they used the acronym CADASIL for the 
first time), and localized the disease to a locus on chromo-
some 19q12. Joutel et al.
2,8 subsequently confirmed that the 
affected gene was Notch3 and identified several mutations 
therein.
Epidemiology
The exact prevalence of CADASIL is not known. According 
to a study from west Scotland, the disease prevalence was 
1.98 per 100,000 adults with a probable CADASIL mutation 
prevalence of 4.14 per 100,000 adults.
9 The researchers esti-
mated the prevalence of CADASIL based on data from the 
regional registry. However, this figure could underestimate 
the true prevalence because CADASIL was frequently mis-
diagnosed at that time and they screened only four exons. 
Dong et al.
10 determined the prevalence of CADASIL in a 
stroke population by screening exons 3, 4, 5, and 6 of the 
Notch3 gene in 218 subjects with lacunar stroke. Only one 
young patient exhibited a mutation in exon 4. The overall 
carrier frequency of the CADASIL mutation was 0.05%, and 
it was 2.0% and 11.1% for those with disease onset at ≤65 
years and ≤50 years, respectively. CADASIL has been re-
ported worldwide in many ethnic groups. The number of re-
ported cases of CADASIL is gradually increasing as the 
clinical picture becomes more widely recognized and genetic 
testing becomes available. Most large reported clinical series 
have been from European countries including France, Ger-
many, the UK, Finland, Italy, and the Netherlands.
11-17 Re-
ports from North America are relatively sparse, especially 
considering the high level of academic activity in this region. 
CADASIL families have been increasingly described in oth-
er world regions, including Asia, the Middle East, Australia, 
South America, and Africa. 
Pathophysiology
The Notch3 gene encodes cell-surface receptors that trans-
duce signals between neighboring cells.
18 The Notch signal-
ing pathway is highly conserved during evolution and is im-
portant for cell fate during embryonic development. Notch3 
expression is restricted to vascular smooth-muscle cells (VS-
MC) in adults and participates in vascular development, dif-
ferentiation, and remodeling.
19,20 The NOTCH3 receptor is a 
single-pass transmembrane receptor of 2,321 amino acids. It 
consists of a large extracellular domain (ECD) with 34 tan-
dem epidermal growth factor (EGF)-like repeats, three Notch/
Lin12 repeats, a transmembrane domain, and an intracellular 
domain. Each EGF-like repeat contains six cysteine residues. 
The large ECD is noncovalently bound to the intracellular 
domain. Ligand binding leads to a proteolytic cleavage that 
translocates the intracellular domain to the nucleus. The in-
tracellular domain activates the transcription factor RBPJk 
and other coactivators.
Knowledge of the effects of CADASIL-associated muta-
tions on NOTCH3 function is important to understanding the 
molecular pathogenesis of this disorder. A small number of 
mutations located in the ligand-binding domain (EGF repeats 
10 and 11) produce a significant reduction in transcriptional 
activity.
21 However, greater numbers of mutations outside the 
ligand-binding domain lead to normal levels of signaling ac-
tivity. Researchers have recently investigated the effects of 
mutations located in the ligand-binding domain in compari-
son with other common mutations.
22 
Patients with mutations in the ligand-binding domain showed 
significantly higher scores on cognitive scales, suggesting 
that reduced Notch3 signaling acts only as a modifier of the 
CADASIL phenotype. Therefore, Notch3 mutations do not 
cause functional abnormalities in the Notch canonical path-
way, and loss of function of the Notch3 gene is probably not 
the cause of CADASIL. 
Accumulation of the NOTCH3 ECD in the arterial wall is 
a characteristic finding of patients with CADASIL.
19 A re-
cent study showed that both wild-type and CADASIL-mu-
tated NOTCH3 ECDs spontaneously form oligomers and Choi JC
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higher order multimers in vitro.
23 Notably, mutations causing 
CADASIL enhanced the formation of multimers in compari-
son with wild-type protein. 
These findings implicate the neomorphic effects of CA-
DASIL mutations as a pathogenetic mechanism underlying 
degeneration of VSMC. Nonetheless, whether the accumula-
tion of the NOTCH3 ECD is the cause or the result of VSMC 
degeneration is not known. At present, the exact molecular 
mechanisms linking Notch3 mutations to degeneration of 
VSMC are uncertain.
Genetics
Over 170 different mutations have been identified in CADA-
SIL, more than 95% of which are missense point mutations.
24 
Most of the mutations are located in exons 2-24, which en-
code the ECD of the NOTCH3 receptor. Of all the reported 
mutations, 62% are located in exons 3, 4, 5 and 8, and an ad-
ditional 18% are located in exons 2, 6, 11, and 18. However, 
the reported distribution of mutations has varied with the 
world region.
14,17,25 Almost all mutations lead to an odd num-
ber of cysteine residues in the affected EGF. However, a small 
number of reports describe mutations not involving cyste-
ine.
26-29 Because full exons were not screened
26 or skin biop-
sies were not performed,
27 whether cysteine-sparing mutations 
cause CADASIL remains debatable. Scheid et al.
29 recently 
found deposits of granular osmiophilic material (GOM) be-
tween the smooth-muscle cells of small arteries and positive 
immunostaining with a NOTCH3 monoclonal antibody in pa-
tients with cysteine-sparing mutations. No other mutation was 
found in the remaining exons. However, a more complex re-
arrangement in the Notch3 gene that is not revealed by current 
molecular analysis remains a possibility. Two patients with 
de novo mutations have been described to date.
30,31 These find-
ings suggest that the absence of a family history does not rule 
out a diagnosis of CADASIL, and hence CADASIL may be 
more frequent than currently thought. In addition, patients 
homozygous for CADASIL mutations have been described, 
and their clinical features lie within the normal spectrum of 
CADASIL in comparison to age-matched heterozygous pa-
tients.
32 Therefore, CADASIL follows the typical pattern of an 
autosomal dominant disease in which heterozygous and ho-
mozygous patients are clinically indistinguishable. 
The founder effect refers to a type of genetic drift that ac-
counts for elevated disease frequencies in small isolated 
populations. Several reports have suggested that CADASIL 
is influenced by this phenomenon. For example, evidence of 
a founder effect has been seen in both island populations, 
such as Taiwan and Jeju, and inland areas, including Finland 
and middle Italy, due to observed clustering of the same mu-
tation.
14,17,33,34 Finally, a novel heterozygous missense muta-
tion (c.4544T>C) in exon 25 of Notch3 gene was reported in 
a patient with cerebral SVD but lacking deposits of GOM 
and NOTCH3 accumulation.
35 This mutation results in in-
creased canonical Notch3 signaling. This finding suggests that 
CADASIL is not the only cerebral SVD caused by Notch3 
mutations.
Pathology
On autopsy, the brains of CADASIL patients show mild dif-
fuse cerebral atrophy with multiple lacunar infarctions in the 
periventricular white matter, basal ganglia, thalamus, mesen-
cephalon, and pons.
36 The centrum semiovale shows diffuse 
loss of myelin with preservation of the subcortical U-fibers. 
Although on gross examination the cerebral cortex appears 
to be unaffected, neuronal apoptosis may be found in cortical 
layers, the severity of which correlates with the extent of 
ischemic lesions in the white matter.
37 Histologically, medul-
lary and leptomeningeal arterioles show thickening of the 
media. In addition, the walls of affected arterioles show de-
generation of VSMC and deposition of granular eosinophilic 
material. Arteriolar stenosis is frequently observed along 
with severe thickening of arteriole walls that is more pro-
nounced in the white matter than in the gray matter.
38 Al-
Fig. 1. Characteristic pathologic findings in CADASIL on electron 
microscopy. An arteriole obtained during a skin biopsy shows 
multiple GOMs (arrow) between the basement membranes of 
VSMC (Courtesy of Sung-Hye Park, MD, PhD). CADASIL: cerebral 
autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy, GOMs: granular osmiophilic materials, 
VSMC: vascular smooth-muscle cell.CADASIL
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though the walls of lenticular nucleus arterioles were also 
thickened, definite stenosis was not observed in this region 
in comparison to the white matter.
39 With the exception of the 
granular deposits, other pathologic findings did not differ 
significantly from those observed in other common cerebral 
SVDs. GOM refers to small or medium-size (20-40 μm) ex-
tracellular electron-dense granular deposits that are observed 
on electron microscopy (Fig. 1) and located near the VSMC 
of arterioles or veins.
36,40 The exact composition of GOM is 
disputed. Joutel et al.
19 showed that NOTCH3 ECDs accu-
mulate at the cytoplasmic membrane of VSMC, in close vi-
cinity to but not within the GOM. However, other research-
ers have used immunoelectron microscopy to show that 
NOTCH3 ECDs are abundantly and evenly distributed with-
in the GOM, suggesting that they are a major component of 
GOM.
41 Ultrastructural studies have shown destruction of 
VSMC and the presence of GOM in muscle and skin biop-
sies from patients with CADASIL. These findings have spe-
cial clinical importance because skin and muscle biopsies 
could be useful for diagnosing CADASIL.
42,43
Clinical Features
Ischemic stroke
Ischemic stroke is the most common clinical manifestation 
of CADASIL, being present in 60-84% of patients (Table 
1).
11,12,44 The mean age at stroke onset is reportedly 41-49 
years and most of the patients present with typical lacunar 
syndrome manifesting as pure motor or pure sensory strokes, 
dysarthria or clumsy hand syndrome, and ataxic hemiparesis. 
Some patients show an insidious or stepwise evolution last-
ing up to several days. Although one study found that large 
cerebral arteries were involved in 20-30% of the patients, 
symptomatic stenosis was rare.
45 ICH has been described 
only sporadically in patients with CADASIL. However, re-
cent studies from Korea and Taiwan found that 25% of symp-
tomatic patients with CADASIL had ICHs, with their devel-
opment being closely related to the number of cerebral mi-
crobleeds (CMB).
33,46 The presence of ICHs was found to be 
independently associated with poor clinical outcome in our 
patients with CADASIL (unpublished data).
Almost 70% of the patients who suffer from an initial 
stroke experience recurrent strokes, and some of them devel-
op vascular parkinsonism and pseudobulbar palsy following 
recurrent subcortical infarctions.
44 The mean incidence rate 
of stroke during a 2-year follow-up of 80 CADASIL patients 
was found to be 10.4 per 100 person-years.
47 Vascular risk 
factors have been found only infrequently in patients with 
CADASIL in large clinical series, with hypertension reported 
in 6.6-28.6% of the patients and diabetes mellitus in 4.0-9.5% 
of the patients. The presence of vascular risk factors was not 
associated with age at the onset or presence of stroke in CA-
Table 1. Summary of the main clinical manifestations of CADASIL
Symptom
Frequency 
(%)
Mean age at 
onset (years)
Characteristics
Ischemic stroke 60-84 41-49 Usually presents with typical lacunar syndrome.
Almost 70% of the patients experience recurrent strokes.
Vascular parkinsonism and pseudobulbar palsy following recurrent 
  subcortical infarctions.
Vascular risk factors are not associated with stroke.
Dementia 19-42 58 Cognitive deficit in about 60% of patients.
Two-thirds of patients develop dementia by 65 years of age.
Characteristic frontal-lobe cognitive deficits even before patients 
  experience an ischemic stroke.
Cognitive deficits typical of subcortical vascular dementia.
Severity is closely associated with the number of lacunar infarctions.
Migraine 22-77 26-30 Eighty percent of migraine patients report a preceding aura.
Many patients experience basilar migraine, hemiplegic migraine, 
  and migraine with prolonged aura.
Intensity and frequency of migraine attacks tend to decrease after 
  the first ischemic stroke.
Psychiatric disturbance 20-41 Not available Usually occur during the disease course.
Mood disorders are the most common.
Most psychotic events occur in patients with underlying dementia.
Epileptic seizure 05-10 50 Typically occurs late in the disease course.
Most patients have a history of stroke and dementia.
Usually presents with generalized tonic-clonic seizures.
CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.Choi JC
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DASIL patients.
16
Cognitive deficits
Cognitive deficit is the second most frequent symptom, be-
ing found in about 60% of CADASIL patients. Dementia has 
been observed in 19-41% of the patients, with two-thirds of 
patients developing dementia by 65 years of age.
11,12,16,44 How-
ever, recent studies from Asia found a relatively low (4.8-
6.0%) prevalence of dementia in spite of the advanced mean 
age of the patients.
33,46 However, because both studies found 
a dominant R544C mutation, this low prevalence of demen-
tia might reflect an inherent characteristic of that mutation. 
Patients with CADASIL show characteristic frontal-lobe 
cognitive deficits, including problems with executive func-
tion, working memory, and verbal fluency. These symptoms 
can be confirmed by detailed neuropsychological testing 
even before the patient experiences an ischemic stroke.
48,49 
Patients with episodic memory dysfunction exhibit difficul-
ties in retrieval rather than encoding. As the disease pro-
gresses, patients begin to show cognitive deficits typical of 
subcortical vascular dementia. The severity of cognitive defi-
cit is closely associated with the number of lacunar infarc-
tions seen in brain magnetic resonance imaging (MRI). How-
ever, volume of the white-matter high-signal-intensity (HSI) 
lesions was not significantly associated with the severity of 
the cognitive deficit in CADASIL after adjusting for age.
50 
Migraine
Migraine is the most common initial symptom in patients 
with CADASIL, with a reported incidence of 22-77%.
11,12,16 
Migraine usually starts around 20 years of age, and appears 
in 90% of patients by 40 years of age. Eighty percent of mi-
graine patients report a preceding aura, and substantial num-
bers of patients experience basilar migraine, hemiplegic mi-
graine, and migraine with prolonged aura. Compared with mi-
graine in the general population, migraine in CADASIL pa-
tients has an older age at onset and higher incidence of aura, 
and it presents with atypical aura. The intensity and frequen-
cy of migraine attacks tend to decrease, with a small number 
of patients never developing migraine after they experience 
the first ischemic stroke. Nonetheless, the exact mechanism 
of migraine attack in patients with CADASIL is uncertain. 
Because migraines normally appear 10 years earlier than the 
ischemic stroke and the clinical features do not differ be-
tween patients with and without migraine, these headaches 
are probably not caused by brain ischemia. Interestingly, 
Asian studies, including those from Korea, Japan, and China, 
have found a lower prevalence (0-26.9%) of migraine, mak-
ing the clinical detection of CADASIL even more difficult in 
these regions.
26,33,34,51
Psychiatric disturbance
Psychiatric illness occurs in 20-41% of patients with CADA-
SIL. Mood disorders are the most common,
11,12,44,52 with the 
other psychiatric illnesses including conversion disorder, 
anxiety disorder, behavioral and personality disorder, psy-
chosis and delusion, drug dependence, and alcoholism. Psy-
chiatric disturbances in patients with CADASIL usually ap-
pear during the course of the disease, but they seldom repre-
sent the symptom at onset and are transient in most cases. 
Most psychotic events occur in patients with underlying de-
mentia. Apathy is a frequent clinical feature of vascular de-
mentia, and a recent study found that 41% of CADASIL pa-
tients had apathy apart from depression.
53 Apathetic patients 
were older than nonapathetic subjects, had a lower cognitive 
score, had greater global disability, and presented with higher 
frequencies of depression and additional neuropsychiatric 
symptoms.
Other manifestations
Typically 5-10% of CADASIL patients develop epileptic sei-
zures, which normally occur late in the course of the ill-
ness.
11,12,16 Most patients that develop a seizure disorder have 
a history of stroke and dementia. Patients typically present 
more frequently with generalized tonic-clonic seizures than 
with focal seizure. A small number of patients present with 
acute reversible encephalopathy with fever, confusion, coma, 
and seizure lasting several days. A high prevalence (47%) of 
large right-to-left shunt was recently found in patients with 
CADASIL using a transcranial Doppler.
54 However, the clin-
ical significance of this presentation is uncertain because no 
clinical or MRI differences have been found between pa-
tients with and without shunt.
Clinical Course and Prognosis
The clinical course of CADASIL is highly variable even wi-
thin families, with the age at the onset of stroke, dementia, and 
migraine possibly differing by 20 years among members of 
the same family.
12,16 Therefore, there appears to be a weak 
correlation between genotype and phenotype. Some patients 
show a rapid progression to severe disability, whereas other 
patients remain stable or even improve. A large retrospective 
study from Germany found that conventional vascular risk 
factors such as hypertension, diabetes mellitus, and hyper-
cholesterolemia did not influence the age at the onset or de-
velopment of stroke.
15 The median survival time of men in 
that study was significantly shorter than that expected from 
German life tables (64.6 vs. 69.3 years, p=0.01). In contrast, 
the median survival time of women was not significantly re-
duced (70.7 vs. 72.2 years). Although the median age at the CADASIL
6  J Clin Neurol 2010;6:1-9
onset of stroke did not differ between men and women, the 
median ages at the onset of the inability to walk without as-
sistance, bedriddenness, and death were significantly lower in 
men than in women. Pneumonia was the most frequent cause 
of death, followed by sudden unexpected death and asphyxia. 
Brain Imaging
The most characteristic brain MRI findings in patients with 
CADASIL are white-matter HSI lesions and multiple lacunar 
infarctions (Fig. 2).
13,55 On T2-weighted images, most patients 
exhibit HSI lesions in the white matter, more frequently in 
the periventricular and deep white matter than in the superfi-
cial white matter. HSI lesions start to appear in the subcorti-
cal white matter at 20 years of age in the absence of deep in-
farcts. These lesions then subsequently extend into the basal 
ganglia, thalamus, and brainstem. The involvement of the an-
terior temporal lobe and external capsule is characteristic, in 
contrast to sporadic ischemic HSI lesions. The sensitivity and 
specificity of the anterior temporal lobe lesions for the diag-
nosis of CADASIL were 90% and 100%, respectively.
56 Un-
like HSI lesions in other white-matter regions, those found in 
the anterior temporal areas were more severe even in young-
er subjects. The sensitivity and specificity of external capsule 
involvement were 93% and 45%, respectively. Lacunar in-
farctions usually appear by 30 years of age in the subcortical 
white matter, basal ganglia, thalamus, internal capsule, and 
brainstem. Lacunar infarcts were found in 75% of patients 
aged 30-40 years, and their number increased with age. CMB 
were found in 31-69% of patients and were located in vari-
ous parts of the brain, preferential in the cortical/subcortical 
regions, white matter, thalamus, and brainstem. They were 
always found outside of ischemic lesions. Among the lesions 
observed in conventional MRI in CADASIL patients, the vol-
ume of lacunar lesion and the presence of CMB were inde-
pendently associated with cognitive function and disabili-
ty.
57,58 Diffusion-tensor imaging detects ultrastructural tissue 
damage even in areas that appear normal in conventional 
MRI. The mean diffusivity was found to be the main predic-
tor of clinical progression in patients with CADASIL.
59 Re-
cent studies have found that cerebral atrophy is independent-
ly associated with the extent of cognitive decline in patients 
with CADASIL, as with other common sporadic subcortical 
ischemic vascular diseases.
60 The change in brain volume 
seems promising as an adjunct outcome measure in future 
interventional trials.
Brain MRI, single-photon-emission computed tomography 
(SPECT), and positron-emission tomography (PET) reveal 
that the cerebral blood flow (CBF) is lower in patients with 
CADASIL than in healthy controls. Hypoperfusion on brain 
SPECT is correlated with MRI ischemic lesions in demented 
patients showing very low blood flows.
61 Chabriat et al.
62 
demonstrated significant reductions in both absolute and rel-
ative CBFs in the white matter of CADASIL patients using 
an MRI bolus-tracking method. This reduction was also more 
severe in demented than in nondemented patients. However, 
no significant change in absolute CBF was observed in the 
cortex of patients with CADASIL. PET showed that CBF in 
the cerebral white matter was lower in young CADASIL pa-
tients than in controls even before the patients had suffered a 
stroke.
63 
Diagnosis
Proper diagnosis of CADASIL is important for several rea-
sons. First, the clinical course and prognosis differ between 
patients with CADASIL and those with other common cere-
bral SVDs. Second, proven therapies for ischemic stroke, in-
cluding thrombolytics, antithrombotics, antihypertensive ag-
ents, and statins, have not been validated for patients with CA-
DASIL. Clinical manifestations including migraine, recurrent 
subcortical stroke, psychiatric illness, and a family history of 
stroke, migraine, and dementia may be helpful in differentiat-
ing CADASIL from more common sporadic SVDs. One study 
showed that the long clinical course (several decades) and 
variable onset of symptoms even within families can result 
in as many as 35% of CADASIL patients being initially mis-
diagnosed with multiple sclerosis, dementia, or central ner-
vous system vasculitis.
64 At the time of first presentation, only 
34% of CADASIL patients have first-degree relatives with a 
A   B   C  
Fig. 2. Typical brain MRI findings in CA-
DASIL. FLAIR images demonstrate HSI 
lesions in the anterior temporal lobe (A) 
and bilateral external capsules (B). Mul-
tiple lacunar infarctions (C) are noted in 
bilateral periventricular and deep white 
matter with punctate HSI lesions. CA-
DASIL: cerebral autosomal dominant 
arteriopathy with subcortical infarcts and 
leukoencephalopathy, FLAIR: fluid at-
tenuated inversion recovery, HSI: high-
signal-intensity.Choi JC
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history of stroke, and only 16% have first-degree relatives 
with a history of stroke prior to 50 years of age. Therefore, 
an initially negative family history should not exclude con-
sidering CADASIL in daily routine clinical diagnoses. 
The initial detection may be even more difficult in Asian 
populations for several reasons:26,33,46 1) Asians show a lower 
prevalence of migraine, 2) studies from Asian regions de-
scribe a lower involvement (22-43%) of the anterior tempo-
ral lobe in brain MRI, and 3) the high prevalence of vascular 
risk factors for SVD such as hypertension in patients with 
CADASIL increases the difficulty of differentially diagnos-
ing CADASIL in Asian patients. Currently the cause of such 
differences between CADASIL patients from Asia and Eu-
rope is unclear. Regional differences in genotype alone may 
not explain this because 1) there are no significant differenc-
es in phenotypes among various genotypes in Asian CADA-
SIL patients and 2) the age at the onset of stroke, dementia, 
and migraine differ among members of the same Asian fami-
lies. Our recent analysis showed that the number of lacunar 
infarctions per patient and the volume of white-matter HSI 
lesions were both lower in Asian patients than in European 
patients in spite of the mean age being higher in the former 
(unpublished data). Asian patients with CADASIL seem to 
show a milder clinical course, although some of them devel-
op ICH, which is associated with hypertension. The lower 
prevalence of ischemic stroke and lacunar infarction may ex-
plain the milder clinical course in Asian populations. The 
cause of such differences is unclear currently. The presence 
of CMB and history of hypertension were closely related to 
the development of ICH. Because ICH is the one of the most 
important factors in determining disability, the strict control 
of blood pressure may be a crucial management issue for As-
ian CADASIL patients. Currently there are certain limitations 
to differentiating CADASIL from sporadic SVD based on a 
clinical examination, family history, and neuroradiological 
findings. More epidemiologic work is required, especially in 
regions from where CADASIL reports are currently lacking.
Genetic analysis or pathological studies are used to con-
firm the diagnosis in a patient suspected of having CADA-
SIL following clinical evaluation or brain MRI. Screening 
whole exons is time-consuming and expensive. Therefore, it 
is more efficient to initiate screening for mutations located in 
exons 3, 4, 5 and 8, which cover 62% of known mutations. 
In addition, including exons 2, 6, 11, and 18 increases the 
coverage to 80%.
24 If the dominant mutations in that region 
are already known, a simple test using restriction enzyme di-
gestion could be performed instead of more complicated DNA 
sequencing. A skin biopsy is easy to perform and its diagnos-
tic specificity is very high since GOM has not been detected 
in any other disorders. However, the reported sensitivity has 
varied from 45% to 100%.
65,66 A recent large retrospective 
study involving 131 Finnish CADASIL patients detected GOM 
in all 131 mutation-positive patients.
24 Therefore, using elec-
tron microscopy to detect GOM in skin biopsies is a highly re-
liable diagnostic method. To maximize the diagnostic sensi-
tivity in skin biopsies, researchers have suggested that the skin 
biopsy should be deep and large enough to include small ar-
terioles located in the deep dermis or upper subcutaneous tis-
sue. If the first biopsy results are negative, a repeated biopsy 
should be considered. Immunostaining for NOTCH3 ECDs 
increases both the sensitivity and specificity to more than 
90%.
67
Treatment
At present there is no specific treatment for patients with CA-
DASIL. The primary treatments are genetic counseling, sup-
portive care, and medications for treating depression, mi-
graine, and the secondary prevention of ischemic stroke. Some 
studies have shown that acetazolamide is an effective treat-
ment for migraine in patients with CADASIL.
68,69 The safety 
and efficacy of migraine-preventing medications (e.g., beta-
blockers and antiepileptic drugs) and migraine-aborting drugs 
(e.g., ergot derivatives and tryptans) have not been demon-
strated. It is reasonable to control vascular risk factors such 
as hypertension and hypercholesterolemia considering the 
high recurrence rate of ischemic stroke in CADASIL. How-
ever, the effect of such treatments on the prognosis of CA-
DASIL is uncertain. A two-center cohort study found that 
blood pressure and hemoglobin A1c were significantly asso-
ciated with the presence of CMB, which in turn was indepen-
dently associated with greater disability but not with demen-
tia.
58 Our previous study showed that the presence of CMB 
was associated with the development of ICH, which was sig-
nificantly associated with poor functional outcome.
46 These 
findings suggest that controlling the blood pressure and serum 
glucose may improve the clinical course of this disorder. Smok-
ing should be avoided because it was found to be indepen-
dently associated with being younger at the onset of stroke.
16 
However, the effects of antiplatelet agents and anticoagulants 
are uncertain. Anticoagulants are not recommended due to 
several reports of the development of hemorrhagic stroke. A 
recent randomized double-blind trial with the cholinesterase 
inhibitor donepezil showed no effect on the primary endpoint 
in CADASIL patients with cognitive impairment.
70 Improve-
ments were noted on several measures of executive function, 
but the clinical relevance of these findings was unclear. Con-
ventional cerebral angiography resulted in neurological com-
plications in up to 70% of patients in one study, and thus sh-
ould be avoided in patients suspected of CADASIL.
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Conclusion
CADASIL is the most common hereditary cerebral SVD, and 
the number of reports on patients with CADASIL is steadily 
increasing. Although specific treatments for CADASIL pa-
tients are currently unavailable, the disease-causing muta-
tions are well described and active research into the patho-
physiology of the disease is underway. New therapies that 
could prevent or slow the degeneration of VSMC will proba-
bly emerge in the near future, as will clinical studies using spe-
cific neuroimaging surrogate markers to monitor the treat-
ment course. CADASIL is a prototype single-gene disorder 
that has evolved as a unique model for studying the mecha-
nisms underlying cerebral SVDs. At present, the incidence 
and prevalence CADASIL seem to be underestimated due to 
limitations in clinical, neuroradiological, and genetic diagno-
ses of this disorder.
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